Weekly injection for diabetes
Pro Research Analysisby 
Searched over 200M research papers
Weekly Injection Options for Diabetes Management
Introduction to Weekly Injections for Diabetes
Managing diabetes often requires frequent medication administration, which can be burdensome for patients. Recent advancements have introduced once-weekly injection options that aim to improve adherence and glycemic control. This article explores the efficacy and safety of various once-weekly injectable treatments for both type 1 and type 2 diabetes.
Once-Weekly Insulin Icodec for Type 2 Diabetes
Efficacy and Safety
Insulin icodec is a novel basal insulin analogue designed for once-weekly administration. A 26-week randomized trial compared insulin icodec with daily insulin glargine in patients with type 2 diabetes inadequately controlled on oral medications. The study found that insulin icodec had a similar glucose-lowering efficacy to insulin glargine, with a mean reduction in glycated hemoglobin (HbA1c) of -1.33 percentage points compared to -1.15 percentage points for glargine. The safety profiles were also comparable, with low rates of hypoglycemia and other adverse events 17.
Once-Weekly Exenatide for Youth and Adults with Type 2 Diabetes
Pediatric Use
Exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has been evaluated for once-weekly use in pediatric patients with type 2 diabetes. A study involving participants aged 10 to 18 years showed that exenatide significantly reduced HbA1c levels by -0.36% compared to a +0.49% increase in the placebo group over 24 weeks. The treatment was well tolerated, with a similar incidence of adverse events between the exenatide and placebo groups .
Long-Term Efficacy in Adults
In adults, a three-year study compared once-weekly exenatide with daily insulin glargine. The results demonstrated that exenatide maintained a significant reduction in HbA1c levels (-1.01%) compared to glargine (-0.81%). Exenatide also had a lower rate of hypoglycemia and was associated with transient gastrointestinal side effects, which decreased over time .
Once-Weekly Dulaglutide for Youth with Type 2 Diabetes
A 26-week trial assessed the efficacy of once-weekly dulaglutide in youths aged 10 to 18 years. The study found that dulaglutide significantly reduced HbA1c levels by -0.6% and -0.9% for the 0.75 mg and 1.5 mg doses, respectively, compared to a 0.6% increase in the placebo group. The treatment was well tolerated, with gastrointestinal issues being the most common adverse events .
Once-Weekly Semaglutide for Type 2 Diabetes
Transition from Multiple Daily Injections
A study explored the transition from multiple daily injections (MDI) to once-weekly semaglutide in patients with type 2 diabetes. The trial found that semaglutide, combined with basal insulin, effectively maintained HbA1c levels and reduced the need for prandial insulin. The treatment was associated with improved patient satisfaction and a lower risk of hypoglycemia .
Monotherapy Efficacy
Another study evaluated semaglutide monotherapy in treatment-naive patients with type 2 diabetes. Over 30 weeks, semaglutide significantly reduced HbA1c levels by up to -1.55% and body weight by up to -4.53 kg compared to placebo. The most common side effects were gastrointestinal, including nausea and diarrhea .
Once-Weekly Basal Insulin Fc (BIF) for Type 1 and Type 2 Diabetes
Type 1 Diabetes
Basal Insulin Fc (BIF) is a fusion protein designed for once-weekly administration. A 26-week study in patients with type 1 diabetes showed that BIF provided noninferior glycemic control compared to daily insulin degludec, with similar rates of hypoglycemia and other adverse events .
Type 2 Diabetes
In Japanese patients with type 2 diabetes, a phase 1 trial demonstrated that BIF was well tolerated and provided prolonged pharmacokinetic and pharmacodynamic profiles. The treatment maintained stable fasting glucose levels and had a low incidence of hypoglycemic events .
Conclusion
Once-weekly injectable treatments for diabetes, including insulin icodec, exenatide, dulaglutide, semaglutide, and Basal Insulin Fc, offer promising alternatives to daily injections. These treatments have shown efficacy in reducing HbA1c levels and maintaining glycemic control with manageable safety profiles, potentially improving adherence and quality of life for patients with diabetes.
Sources and full results
Most relevant research papers on this topic